Sponsors (15)
The bill increases workplace access to lifesaving naloxone and training—especially at federal and VA sites—while relying on nonmandatory guidance for private employers and creating modest costs and an accelerated rulemaking timeline that may produce uneven adoption and implementation risks.
Employees (private and federal), veterans, healthcare workers, and bystanders will be more likely to have naloxone on site and to receive training, increasing the chance of reversing workplace overdoses.
Federal worksites, including Veterans Health Administration facilities, will be covered by standardized OSHA rulemaking, creating consistent requirements across agencies and ensuring nationwide availability of reversal medication at federal worksites.
Private employers (especially small businesses) receive OSHA-backed, federal best-practice guidance to implement overdose preparedness without imposing new mandatory regulatory burdens.
Because the guidance to private employers is nonmandatory, many workplaces may not adopt naloxone availability or training, leaving uneven protections for employees across employers and sectors.
Costs to procure, store, replenish naloxone and to provide annual training will fall on employers (including small businesses) and federal agencies, increasing operating expenses and potentially raising taxpayer costs.
The 270‑day accelerated deadline for OSHA rulemaking could limit stakeholder input and detailed implementation planning, increasing the risk of uneven rollout or legal challenges.
Based on analysis of 3 sections of legislative text.
OSHA must issue employer guidance and require Federal agencies to stock opioid overdose reversal medication and offer voluntary annual training, with both actions due within 270 days.
Introduced February 10, 2026 by Bonnie Watson Coleman · Last progress February 10, 2026
Requires the Department of Labor (through OSHA) to publish non‑mandatory guidance for employers on acquiring and maintaining opioid overdose reversal medication and offering voluntary annual employee training, and directs OSHA to promulgate regulations that require all Federal agencies to stock such medication and offer voluntary annual training. The guidance and the agency regulations must be issued within 270 days of enactment; the private‑employer guidance is voluntary while the federal‑agency rule is mandatory for Federal workplaces.